|
TSTD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66855418370915E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.32700533789421E-11 |
| Normal-vs-Stage2 |
2.66349999999971E-06 |
| Normal-vs-Stage3 |
4.85944617878431E-13 |
| Normal-vs-Stage4 |
2.22188933918233E-12 |
| Stage1-vs-Stage2 |
7.130000E-01 |
| Stage1-vs-Stage3 |
2.612200E-02 |
| Stage1-vs-Stage4 |
7.599900E-03 |
| Stage2-vs-Stage3 |
7.209700E-02 |
| Stage2-vs-Stage4 |
1.679530E-02 |
| Stage3-vs-Stage4 |
3.710800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5754064719431E-13 |
| Normal-vs-AfricanAmerican |
2.14159999999408E-05 |
| Normal-vs-Asian |
1.02370000032437E-07 |
| Caucasian-vs-AfricanAmerican |
8.680400E-01 |
| Caucasian-vs-Asian |
6.351000E-01 |
| AfricanAmerican-vs-Asian |
8.708400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.45437004053883E-12 |
| Normal-vs-Female |
2.37809771874709E-12 |
| Male-vs-Female |
3.907400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.58689950069402E-10 |
| Normal-vs-Age(41-60Yrs) |
3.30150351501857E-11 |
| Normal-vs-Age(61-80Yrs) |
1.7945644970041E-12 |
| Normal-vs-Age(81-100Yrs) |
1.159490E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.329600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.923900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.177400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.713200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.074800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.953400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.449310E-04 |
| Classical-VS-Follicular |
8.775000E-01 |
| Classical-VS-Other |
2.890000E-01 |
| Classical-VS-Normal |
8.34310398545313E-12 |
| Tall-VS-Follicular |
1.040800E-03 |
| Tall-VS-Other |
5.307200E-01 |
| Tall-VS-Normal |
1.86051174466684E-12 |
| Follicular-VS-Other |
3.368200E-01 |
| Follicular-VS-Normal |
1.40819999994157E-07 |
| Other-VS-Normal |
4.966500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.75589551179678E-11 |
| Normal-vs-N1 |
5.37139999146063E-09 |
| N0-vs-N1 |
4.644400E-01 |
|
|
